Abstract: Disclosed is a protection circuit of a flyback converter and a control method. The protection circuit comprises: an active discharge module, for providing a discharge path between a first current terminal and a second current terminal of a switch transistor in a resonance circuit, and controlling turning-on and turning-off of the discharge path according to a discharge enable signal; in the normal work state of the flyback converter, the discharge path is disconnected, the resonance circuit works, before the flyback converter is restarted, the discharge path is turned on for a predetermined time period to release charges stored in the resonance circuit, and the resonance current after the flyback converter is restarted is reduced to the safe work current of the second switch transistor. The resonance current is discharged before the flyback converter is restarted, thus reducing the resonance current and enhancing system stability and security.

Abstract: Disclosed is a protection circuit of a flyback converter and a control method. The protection circuit comprises: an active discharge module, connected to at least one end of a first capacitor in a resonance circuit of the flyback converter to provide a discharge path, and controlling turning-on and turning-off of the discharge path according to the discharge enable signal; in a normal work state, the discharge path is disconnected, the first capacitor works as a resonance capacitor; before the flyback converter is restarted, the discharge path is turned on for a predetermined time period to release charges of the first capacitor, a resonance current after the flyback converter is restarted is reduced to a safe work current of the second switch transistor. Charges stored in the first capacitor can be discharged to release before the flyback converter is restarted to reduce the resonance current and enhance system stability and security.

Abstract: A high strength glass fiber is prepared by following steps: weighing raw materials according to a mass percentage of 50-60% silica sol, 24-31% aluminum sol, 8-11% magnesia, 4-5% calcium oxide, 0.1-2% titanium dioxide, 0-0.5% ferric oxide, 0.5-2% niobium pentoxide, 0.5-1.5% antimony trioxide, 0.3-1.5% bismuth nitrate, and 0.1-0.5% boric acid. Deionized water is added. The raw material undergoes mixing by ball milling, spray-drying, calcining, isostatic pressing, melting, and wire-drawing. The invention adopts silicon sol, aluminum sol and bismuth nitrate. Through ball milling and spray-drying, silicon aluminum barium plasmas is evenly coated on surface of other oxide powders. Then nano particles, of silica, alumina and bismuth oxide are obtained by calcining.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: A high strength glass fiber is prepared by following steps: weighing raw materials according to a mass percentage of 50-60% silica sol, 24-31% aluminum sol, 8-11% magnesia, 4-5% calcium oxide, 0.1-2% titanium dioxide, 0-0.5% ferric oxide, 0.5-2% niobium pentoxide, 0.5-1.5% antimony trioxide, 0.3-1.5% bismuth nitrate, and 0.1-0.5% boric acid. Deionized water is added. The raw material undergoes mixing by ball milling, spray-drying, calcining, isostatic pressing, melting, and wire-drawing. The invention adopts silicon sol, aluminum sol and bismuth nitrate. Through ball milling and spray-drying, silicon aluminum barium plasmas is evenly coated on surface of other oxide powders. Then nano particles, of silica, alumina and bismuth oxide are obtained by calcining.

Abstract: Chalcogenide glass-ceramic having, for example, the following composition GeSe2—Sb2Se3—CuI, this glass-ceramic comprising at least one crystalline phase, characterised in that the crystallisation rate and the dimensions of the crystals in the crystalline phase are such that the crystals are substantially in contact with each other in such a way that this crystalline phase has an electrical conductivity greater than or equal to 10?4 s·cm?1 which increases under lighting due to the creation of charge carriers within the crystalline phase.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: Chalcogenide glass-ceramic having, for example, the following composition GeSe2—Sb2Se3—CuI, this glass-ceramic comprising at least one crystalline phase, characterised in that the crystallisation rate and the dimensions of the crystals in the crystalline phase are such that the crystals are substantially in contact with each other in such a way that this crystalline phase has an electrical conductivity greater than or equal to 10?4 s·cm?1 which increases under lighting due to the creation of charge carriers within the crystalline phase.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The invention relates to vitreous compositions, in particular of the vitroceramic type, transparent to infrared, production and uses thereof. Said compositions comprise in mol. %: Ge 5-40, Ga<1, S+Se 40-85, Sb+As 4-40, MX 2-25, Ln 0-6, adjuncts 0-30, where M=at least one alkaline metal, selected from Rb, Cs, Na, K and Zn, X=at least one atom of chlorine, bromine or iodine, Ln=at least one rare earth and adjunct=at least one additive comprising at least one metal and/or at least one metal salt with the sum of all molar percentages of the components present in said composition being 100.

Abstract: The invention relates to vitreous compositions, in particular of the vitroceramic type, transparent to infrared, production and uses thereof. Said compositions comprise in mol. %: Ge 5-40, Ga<1, S+Se 40-85, Sb+As 4-40, MX 2-25, Ln 0-6, adjuncts 0-30, where M=at least one alkaline metal, selected from Rb, Cs, Na, K and Zn, X=at least one atom of chlorine, bromine or iodine, Ln=at least one rare earth and adjunct=at least one additive comprising at least one metal and/or at least one metal salt with the sum of all molar percentages of the components present in said composition being 100.

Abstract: The present invention provides compositions and methods for specifically inhibiting host immune responses against expression vectors and target cells transfected with such vectors. In particular, methods of specifically inhibiting the humoral and cellular components of the host immune response to vector-associated antigens and target-cell associated antigens are described.

Abstract: The present invention provides methods and compositions for specifically inhibiting both cellular and humoral immune responses to alloantigen, thereby finding use in extending the survival of transplant allografts and treating graft versus host disease in transplant recipients.